However, trastuzumab should be given to patients with TP53(+)/ERBB2(+) ovarian carcinomas who reached CR, that is, after completion of chemotherapy (in our study 12.4% of all patients), because in this group it might extend DFS time. This evidence concerns the gene TP53 and ovarian carcinoma.